Correction to: Adv Ther (2019) 36:3321–3339 https://doi.org/10.1007/s12325-019-01126-x
On page 3331 of the original article, the word, “/LYXUMIA” has been removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN and the associated reference, numbered 100, has been corrected to: Xultophy® (insulin degludec/liraglutide) [summary of product characteristics]. Bagsvaerd, Denmark: Novo Nordisk A/S https://www.ema.europa.eu/en/documents/product-information/xultophy-epar-product-information_en.pdf. Accessed November 2019.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Handelsman, Y., Muskiet, M.H.A. & Meneilly, G.S. Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Adv Ther 37, 973 (2020). https://doi.org/10.1007/s12325-019-01185-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-019-01185-0